alexa Abstract | New chemical entities of future for infectious diseases

European Journal of Experimental Biology
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


A number of infectious disease treatments are available today. However, infectious diseases still pose serious threats to patients because of the development of antibiotic resistance and the emergence of new infectious diseases. As on date, about 400 drugsincluding New Chemical Entities (NCEs), biologics, vaccines, new dosage forms and drug combinations areat different phases of their development (pre-clinical, Phase I, Phase II, Phase III or preregistration phase) against infectious diseases. This article provides preliminary information about New Chemical Entities (NCEs) for which New Drug Application (NDA) has been submitted by pharmaceutical companies to Food and Drug Administration (FDA) or which are in Phase III of their clinical trial. It would be interesting to see how many of New Chemical Entities (NCEs), among those discussed in this article, will see the face of the future.

To read the full article Peer-reviewed Article PDF image

Author(s): Abida Mohd Imran Mohamed A M Hagga and Said A ElFeky


New Chemical Entities (NCEs), Infectious Diseases, Clinical Trial, U.S. Food and Drug Administration (FDA) and New Drug Application (NDA).

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us